New study tracks safety of VYLOY in everyday cancer care
NCT ID NCT06902545
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors 377 South Korean patients with advanced stomach or gastroesophageal junction cancer who receive VYLOY (zolbetuximab) as part of their normal treatment. Researchers will track side effects and how long the cancer stays stable. The goal is to confirm the drug's safety in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zolbetuximab (VYLOY)
What this could lead to
If successful, this study will confirm the safety of VYLOY in everyday use, supporting its continued approval for advanced gastric and GEJ cancer.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove effectiveness. Side effects may still occur, and results may not apply outside South Korea.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA OR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KR82001
RECRUITINGSeoul, South Korea
-
KR82002
RECRUITINGSeoul, South Korea
-
KR82003
RECRUITINGSeoul, South Korea
-
KR82004
RECRUITINGSeoul, South Korea
-
KR82005
RECRUITINGSeoul, South Korea
-
KR82006
RECRUITINGYangsan, Gyeongsangnam-do, South Korea
-
KR82007
RECRUITINGSeoul, South Korea
-
KR82008
RECRUITINGSuwon, Gyeonggi-do, South Korea
-
KR82009
RECRUITINGSuwon, Gyeonggi-do, South Korea
-
KR82010
RECRUITINGGoyang-si, Gyeonggi-do, South Korea
-
KR82011
RECRUITINGSeoul, South Korea
-
KR82012
RECRUITINGHwasun Gun, Jeollanam-do, South Korea
-
KR82013
RECRUITINGSeoul, South Korea